SQZ Biotechnologies reveals preclinical data on immune cell engineering advances

By The Science Advisory Board staff writers

February 3, 2022 -- SQZ Biotechnologies published preclinical research on the company's ability to engineer multiple immune cell types to drive major histocompatibility class I antigen presentation -- a critical advance in the ability to drive a patient's killer T cells to fight multiple diseases -- in the Journal of Immunology.

The findings comprise a body of work supporting the development of SQZ antigen-presenting cell (APC) and SQZ enhanced antigen-presenting cell cancer vaccine therapeutic programs currently in clinical development, according to a press release.

The publication follows a presentation at the European Society for Medical Oncology Immuno-Oncology congress reporting that the company's lead APC therapeutic candidate induced a radiographic, symptomatic, histologic response as a monotherapy in a late-line head and neck cancer patient.

In the article, SQZ scientists and their collaborators describe how they overcame this fundamental biological problem through the delivery of antigens directly into the cytosol of immune cells by microfluidic squeezing. (J Immunol, February 15, 2022, Vol. 208:4, pp. 929-940).

SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies for patients around the world. The company has active programs in oncology, autoimmune and infectious diseases, as well as additional exploratory initiatives to support future pipeline growth.

SQZ Biotechnologies receives FDA clearance of IND for cancer cell therapy
SQZ Biotechnologies announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for SQZ-eAPC-HPV,...
SQZ Biotechnologies accepted by Roche Accelerator in China
SQZ Biotechnologies, a clinical-stage cell therapy biotechnology company that develops treatments for patients with cancer, infectious diseases, and autoimmune...
How one company aims to make bedside cell therapies a reality
SQZ Biotech is developing high-throughput technology that can manufacture novel cell therapy products in under 24 hours. Founder and CEO Armon Sharei,...

Copyright © 2022 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter